About Omnaris

$11 CO-PAY EVERY TIME

Qualifying patients pay only $11 for every fill* with the OMNARIS

Relief Is Here Program

Learn more

Formulation

Designed to Stick & Stay OMNARIS is the only INS with a unique hypotonic delivery system1,2

Tolerability

Overall incidents of adverse events (AEs) similar to placebo1

Efficacy

24-hour relief of:

  • SAR nasal symptoms...
    all season long1
  • PAR nasal symptoms...
    in patients with year-round nasal allergies1

‡ Symptom relief begins within 24-48 hours after the first dose.
* Restrictions apply. Maximum savings of up to $50, on up to 12 prescription fills of OMNARIS per calendar year. See program rules and eligibility requirements


References

  •  1. OMNARIS [prescribing information]. Marlborough, MA: Sepracor Inc; July 2009.
  •  2. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2007;98(1):12-21.

OMNARIS (ciclesonide) Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and with perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Important Safety Information

Patients using drugs that suppress the immune system are more susceptible to infections. Chickenpox and measles, for example, can have a more serious or even fatal course in children or adults taking corticosteroids. In clinical studies with OMNARIS Nasal Spray, the development of localized infections of the nose and pharynx with Candida albicans has rarely occurred. Intranasal corticosteroids should be used with caution, if at all, in patients with tuberculosis, untreated fungal or bacterial infections, systemic viral or parasitic infections, or ocular herpes simplex.

Patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use a nasal corticosteroid until healing has occurred.

Rare instances of nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure have been reported following the intranasal application of corticosteroids. Close follow-up is warranted in patients with a change in vision and with a history of glaucoma and/or cataracts.

If recommended doses of intranasal corticosteroids are exceeded, or in susceptible individuals used at recommended dosages, symptoms of hypercorticism may occur. If such changes occur, topical corticosteroids should be discontinued slowly.

Intranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. The growth of pediatric patients receiving intranasal corticosteroids, including OMNARIS Nasal Spray, should be monitored routinely.

The most common side effects that may occur with OMNARIS are headache, epistaxis, nasopharyngitis and ear pain.

©2010 Sepracor Inc.and SEPRACOR are registered trademarks of Sepracor Inc.

OMNARIS is a registered trademark of Nycomed GmbH, used with permission.

Sepracor